BR112022017099A2 - COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING RIPK1, METHOD FOR TREATMENT OF A RIPK1-MEDIATED DISEASE AND METHOD FOR TREATMENT OF CNS DAMAGE - Google Patents

COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING RIPK1, METHOD FOR TREATMENT OF A RIPK1-MEDIATED DISEASE AND METHOD FOR TREATMENT OF CNS DAMAGE

Info

Publication number
BR112022017099A2
BR112022017099A2 BR112022017099A BR112022017099A BR112022017099A2 BR 112022017099 A2 BR112022017099 A2 BR 112022017099A2 BR 112022017099 A BR112022017099 A BR 112022017099A BR 112022017099 A BR112022017099 A BR 112022017099A BR 112022017099 A2 BR112022017099 A2 BR 112022017099A2
Authority
BR
Brazil
Prior art keywords
ripk1
treatment
compound
pharmaceutical composition
inhibiting
Prior art date
Application number
BR112022017099A
Other languages
Portuguese (pt)
Inventor
Lewis Richard
Hamilton Matthew
Ray William
Alvarez Fernando
Reyna Naphtali
Kesava Vijayan RAMASWAMY Suyambu
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR112022017099A2 publication Critical patent/BR112022017099A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA INIBIÇÃO DE RIPK1, MÉTODO PARA TRATAMENTO DE UMA DOENÇA MEDIADA POR RIPK1 E MÉTODO PARA TRATAMENTO DE LESÃO NO SNC. São divulgados no presente documento compostos que inibem RIPK1, composições farmacêuticas e métodos para tratamento de doenças mediadas por RIPK1, tais como distúrbios neurodegenerativos, distúrbios inflamatórios e câncer.COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING RIPK1, METHOD FOR TREATMENT OF A RIPK1-MEDIATED DISEASE, AND METHOD FOR TREATMENT OF CNS DAMAGE. Disclosed herein are compounds that inhibit RIPK1, pharmaceutical compositions and methods for treating RIPK1-mediated diseases such as neurodegenerative disorders, inflammatory disorders and cancer.

BR112022017099A 2020-02-28 2021-02-26 COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING RIPK1, METHOD FOR TREATMENT OF A RIPK1-MEDIATED DISEASE AND METHOD FOR TREATMENT OF CNS DAMAGE BR112022017099A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062983356P 2020-02-28 2020-02-28
PCT/US2021/019797 WO2021173917A1 (en) 2020-02-28 2021-02-26 Inhibitors of receptor interacting protein kinase i for the treatment of disease

Publications (1)

Publication Number Publication Date
BR112022017099A2 true BR112022017099A2 (en) 2022-11-16

Family

ID=77491532

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017099A BR112022017099A2 (en) 2020-02-28 2021-02-26 COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING RIPK1, METHOD FOR TREATMENT OF A RIPK1-MEDIATED DISEASE AND METHOD FOR TREATMENT OF CNS DAMAGE

Country Status (10)

Country Link
US (1) US20230159508A1 (en)
EP (1) EP4110765A4 (en)
JP (1) JP2023515971A (en)
CN (1) CN115515940A (en)
AU (1) AU2021225921A1 (en)
BR (1) BR112022017099A2 (en)
CA (1) CA3169099A1 (en)
IL (1) IL295975A (en)
MX (1) MX2022010693A (en)
WO (1) WO2021173917A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
CA3155259A1 (en) 2019-09-27 2021-04-01 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
CA3162605A1 (en) * 2019-11-26 2021-06-03 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1348706B1 (en) * 2000-12-08 2009-08-19 Takeda Pharmaceutical Company Limited Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
EP1424336A4 (en) * 2001-09-03 2004-11-10 Takeda Chemical Industries Ltd 1,3-benzothiazinone derivatives and use thereof
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
TWI648273B (en) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 Heterocyclic amides as kinase inhibitors (III)
CA3094197C (en) * 2015-07-02 2023-02-28 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
CN109843886B (en) * 2016-10-17 2022-04-19 豪夫迈·罗氏有限公司 Bicyclic pyridone lactams and methods of use thereof
ES2956087T3 (en) * 2018-05-03 2023-12-13 Rigel Pharmaceuticals Inc RIP1 inhibitory compounds and methods for preparing and using the same
CN111138448B (en) * 2018-11-02 2022-08-02 中国科学院上海药物研究所 Heterocyclic amides inhibiting RIP1 kinase and uses thereof
WO2021046515A1 (en) * 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
JOP20220062A1 (en) * 2019-09-06 2023-01-30 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same
AR121717A1 (en) * 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc RIP1K INHIBITORS

Also Published As

Publication number Publication date
US20230159508A1 (en) 2023-05-25
WO2021173917A1 (en) 2021-09-02
EP4110765A1 (en) 2023-01-04
CN115515940A (en) 2022-12-23
IL295975A (en) 2022-10-01
JP2023515971A (en) 2023-04-17
MX2022010693A (en) 2022-09-26
EP4110765A4 (en) 2024-03-06
AU2021225921A1 (en) 2022-09-22
CA3169099A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
BR112022017099A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING RIPK1, METHOD FOR TREATMENT OF A RIPK1-MEDIATED DISEASE AND METHOD FOR TREATMENT OF CNS DAMAGE
BR112022010082A2 (en) COMPOUND OF STRUCTURAL FORMULA I OR SALT THEREOF, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUND AND USE OF THE PHARMACEUTICAL COMPOSITION
SA517390509B1 (en) Tricyclic Derivative Compound, Method for Preparing Same, and Pharmaceutical Composition Comprising Same
CL2021000355A1 (en) Ptpn11 inhibitors
BR112021020637A2 (en) Tetrahydro-1h-cyclopenta[cd]indene derivatives as inhibitors of hypoxia-inducible factor -2(alpha)
MX2022001295A (en) Kif18a inhibitors.
BR112017019287A2 (en) compound, pharmaceutically acceptable composition, cancer treatment method, process for preparing the compound of formula I, method for treating cancer, and kit
BR112017020895A2 (en) Indolamine-2,3-dioxigenase inhibitors for cancer treatment
ECSP088693A (en) HYDANTOIN-BASED QUINASE INHIBITORS
BR112017018092A2 (en) compound, pharmaceutical composition, and method for treating and / or preventing a disease or disorder.
BR112017017349A2 (en) compound, composition, method for treating a disorder
BR112018069147A2 (en) compound of formula iii, pharmaceutical composition, fimh function inhibition method and method of treating a fimh mediated disease
MX2023000100A (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS.
BR112022005627A2 (en) COMPOUND OF STRUCTURAL FORMULA I OR A SALT THEREOF, PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND
BR112017000132A2 (en) compound, pharmaceutical composition and method of treating or preventing a disease responsive to inhibition of pi3k activity
CL2022001887A1 (en) Substituted pyrazolo-pyrimidines and uses thereof
MX2022007171A (en) Cyclic compounds and methods of using same.
BRPI0713381A2 (en) compound, pharmaceutical composition, and method for treating a disease
CL2023001339A1 (en) A magl inhibitor.
MX2023001296A (en) Compositions and methods for treating diseases and disorders.
BR112022003584A2 (en) Perk inhibitor pyrrolopyrimidine compounds
SA522441965B1 (en) Tetrazole derivatives as trpa1 inhibitors
BR112023015425A2 (en) URACILA DERIVATIVES AS TRPA1 INHIBITORS
UY38455A (en) NEW INHIBITING COMPOUNDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE (H-PGDS)
BR112023021510A2 (en) METHODS OF TREATMENT OF ESOPHAGEAL STENOSIS

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 239/47 , C07D 239/48 , C07D 239/49

Ipc: C07D 239/47 (2006.01), C07D 239/48 (2006.01), C07D